Last update 06 Dec 2024

APL-5125

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
APL 5125, APL-5125, APL5125
Target-
Mechanism
kinase inhibitor
Therapeutic Areas
NeoplasmsDigestive System DisordersEndocrinology and Metabolic Disease+ [3]
Active Indication
Appendiceal NeoplasmsBile Duct NeoplasmsColorectal Cancer+ [7]
Inactive Indication-
Originator Organization
Apollo Therapeutics No. 2 LLPApollo Therapeutics No. 2 LLPStartup
Active Organization
Apollo Therapeutics No. 2 LLPApollo Therapeutics No. 2 LLPStartup
Inactive Organization-
Drug Highest PhasePhase 1/2
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with APL-5125
NCT06399757 / RecruitingPhase 1/2
A Phase 1/2 Study to Assess the Safety and Antitumor Activity of APL-5125 in Adults With Selected Advanced Solid Tumors
100 Clinical Results associated with APL-5125
Login to view more data
100 Translational Medicine associated with APL-5125
Login to view more data
100 Patents (Medical) associated with APL-5125
Login to view more data
100 Deals associated with APL-5125
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Appendiceal NeoplasmsPhase 2
US
Apollo Therapeutics No. 2 LLPApollo Therapeutics No. 2 LLPStartup
18 Jun 2024
Bile Duct NeoplasmsPhase 2
US
Apollo Therapeutics No. 2 LLPApollo Therapeutics No. 2 LLPStartup
18 Jun 2024
Colorectal CancerPhase 2
US
Apollo Therapeutics No. 2 LLPApollo Therapeutics No. 2 LLPStartup
18 Jun 2024
Locally Advanced Malignant Solid NeoplasmPhase 2
US
Apollo Therapeutics No. 2 LLPApollo Therapeutics No. 2 LLPStartup
18 Jun 2024
Ovarian CancerPhase 2
US
Apollo Therapeutics No. 2 LLPApollo Therapeutics No. 2 LLPStartup
18 Jun 2024
Pancreatic adenocarcinomaPhase 2
US
Apollo Therapeutics No. 2 LLPApollo Therapeutics No. 2 LLPStartup
18 Jun 2024
Prostatic CancerPhase 2
US
Apollo Therapeutics No. 2 LLPApollo Therapeutics No. 2 LLPStartup
18 Jun 2024
stomach adenocarcinomaPhase 2
US
Apollo Therapeutics No. 2 LLPApollo Therapeutics No. 2 LLPStartup
18 Jun 2024
Triple Negative Breast CancerPhase 2
US
Apollo Therapeutics No. 2 LLPApollo Therapeutics No. 2 LLPStartup
18 Jun 2024
uterus adenocarcinomaPhase 2
US
Apollo Therapeutics No. 2 LLPApollo Therapeutics No. 2 LLPStartup
18 Jun 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free